Opioid-Induced Constipation (OIC) market studied was anticipated to grow with a CAGR of nearly 4.5% during the forecast period, 2022-2027.
Opioid use at high doses and for long periods of time can impair immune system function, complicating the course of COVID-19 disease. In various stages of the COVID-19, potential suppression of parts of the immune response may be important in prevention, clinical support, and therapeutic use of medications.
The major factor attributing to the growth of the market is an increasing number of geriatric patients as these patients use opioid analgesics such as morphine, hydromorphone, codeine, etc. as a prescription for chronic non-cancer pain which has severe adverse effects on the digestive system resulting in huge demand for OIC drugs. For instance, according to the Center for Diseases Control and Prevention November 2021, the number of OIC prescriptions increased by 153,260,450 in 2019 and 142,816,781 in 2020. Thus, the rising volume of patient pool with opioid users demands efficient medication for OIC ailments which is likely to fuel the Opioid-Induced Constipation market over the forecast period.
The geriatric population is expected to have a significant impact on the market studied as people aged above 65 are more prone to chronic diseases. According to the World Health Organization Facts of 2021, the proportion of the global population aged 60 and up will nearly double from 12% to 22% between 2015 and 2050. Furthermore, according to the World Health Organization, by 2030, 1 out of every 6 people on the planet will be 60 years old or older. The number of people aged 60 and up is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. By 2050, the global population of people aged 60 and above will get double to reach 2.1 billion. Between 2020 and 2050, the number of people aged 80 and above is expected to triple, reaching 426 million. Thus, increasing use of opioid analgesic prescriptions along with growing geriatric population in developed nations boosting the market over the forecast period.
However, lack of awareness about OIC among the patients considering it as a syndrome resulting in a preference for general laxatives and ongoing research activities to develop next-generation analgesics to replace opioids are likely to hamper the market growth. In contrast, the rise in the global geriatric population preferring for OIC drugs for efficient, rapid relief and awareness among the developed nations is expected to boost the growth of the market.
The Mu-opioid receptor antagonists are expected to account for a large revenue share over the forecast period. This dominance is owing to the availability of various types of products launched by the key players that are suitable for various symptoms in the OIC and the rise in research activities in the segment. A few of the drugs that are readily available in the market for OIC indication are Methylnaltrexone (Relistor), Naldemedine (Symproic), Naloxegol (Movantik), and Alvimopan (Entereg).
Moreover, as per the study titled "Peripheral acting mu-opioid receptor antagonists in the treatment of opioid-induced constipation: a review" published in RESED Journal in September 2020, studies the recently launched Mu-opioid receptor antagonists for their safety and efficacy and concluded that PAMORA had shown efficacy in the treatment of OIC when compared to placebo and in different patient populations, as well as in the case of Naloxegol when compared to laxatives. Metilnaltrexona was studied and approved for patients with advanced cancer pain or other diseases, whereas Alvimopan and Naloxegol were for non-cancer patients. Thus increasing availability of Mu-opioid Receptor Antagonists anticipated the segment growth over the forecast period.
Furthermore, in February 2021, RedHill Biopharma Ltd. signed agreements with Cosmo Pharmaceuticals NV to manufacture two key products; Movantik(μ-opioid receptor antagonist), and RHB-204, currently in a Phase 3 United States study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease.
Additionally, the availability of Relistor in both tablet and subcutaneous injection forms, which is more effective at reversing OIC than other drugs, is expected to drive the segment and contribute to global market revenue over the forecast period.
North America is expected to dominate the overall opioid-induced constipation market throughout the forecast period. Dominance is due to the growing prevalence of various GI disorders among geriatric patients in the United States and a steep rise in the consumption of opioids in Canada in recent years.
According to the Center for Diseases Control and Prevention 2020, in the United States, the overall opioid dispensing rate in 2020 was 43.3 prescriptions per 100 people. Thus increasing number of OIC prescriptions in the United States boot the market over the forecast period.
Furthermore, according to the study titled "Naldemedine for the treatment of opioid-induced constipation in adults with chronic noncancer pain" published in the Future Medicine In June 2020, Naldemedine appears to be an effective and safe first-line therapy for the treatment of opioid-induced constipation in adults with chronic noncancer pain. Thus, rising product development in the country and several clinical studies are expected to boost the market in the region.
However, product approval and market launch by the key market players are anticipated to drive the market in the country. For instance, in December 2021, Sandoz launched an authorized generic of Narcan (naloxone hydrochloride) Nasal Spray 4 mg in the United States to help people who have overdosed on opioids. Furthermore, the increased availability of advanced healthcare infrastructure and earlier approval of OIC drugs owing to the accelerated drug approval initiative by the United States Food and Drug Administration is also likely to fuel the market growth in this region.
The Opioid Induced Constipation market is moderately competitive and consists of several major players. Some of the companies are expanding their market position by adopting various strategies such as acquisitions and mergers, while others are developing new methods for the treatment and introducing new products to maintain their market share. A few of the major players currently dominating the industry in terms of revenue are AstraZeneca plc, Mallinckrodt Pharmaceuticals, Bausch Health (Salix Pharmaceuticals Inc), Merck & Co Inc, and Shionogi & Co Ltd.
This product will be delivered within 2 business days.
Opioid use at high doses and for long periods of time can impair immune system function, complicating the course of COVID-19 disease. In various stages of the COVID-19, potential suppression of parts of the immune response may be important in prevention, clinical support, and therapeutic use of medications.
The major factor attributing to the growth of the market is an increasing number of geriatric patients as these patients use opioid analgesics such as morphine, hydromorphone, codeine, etc. as a prescription for chronic non-cancer pain which has severe adverse effects on the digestive system resulting in huge demand for OIC drugs. For instance, according to the Center for Diseases Control and Prevention November 2021, the number of OIC prescriptions increased by 153,260,450 in 2019 and 142,816,781 in 2020. Thus, the rising volume of patient pool with opioid users demands efficient medication for OIC ailments which is likely to fuel the Opioid-Induced Constipation market over the forecast period.
The geriatric population is expected to have a significant impact on the market studied as people aged above 65 are more prone to chronic diseases. According to the World Health Organization Facts of 2021, the proportion of the global population aged 60 and up will nearly double from 12% to 22% between 2015 and 2050. Furthermore, according to the World Health Organization, by 2030, 1 out of every 6 people on the planet will be 60 years old or older. The number of people aged 60 and up is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. By 2050, the global population of people aged 60 and above will get double to reach 2.1 billion. Between 2020 and 2050, the number of people aged 80 and above is expected to triple, reaching 426 million. Thus, increasing use of opioid analgesic prescriptions along with growing geriatric population in developed nations boosting the market over the forecast period.
However, lack of awareness about OIC among the patients considering it as a syndrome resulting in a preference for general laxatives and ongoing research activities to develop next-generation analgesics to replace opioids are likely to hamper the market growth. In contrast, the rise in the global geriatric population preferring for OIC drugs for efficient, rapid relief and awareness among the developed nations is expected to boost the growth of the market.
Key Market Trends
The Mu-opioid Receptor Antagonists in Drug Class Segment are Expected to Hold the Large Market Share in the Opioid-Induced Constipation Market
The Mu-opioid receptor antagonists are expected to account for a large revenue share over the forecast period. This dominance is owing to the availability of various types of products launched by the key players that are suitable for various symptoms in the OIC and the rise in research activities in the segment. A few of the drugs that are readily available in the market for OIC indication are Methylnaltrexone (Relistor), Naldemedine (Symproic), Naloxegol (Movantik), and Alvimopan (Entereg).
Moreover, as per the study titled "Peripheral acting mu-opioid receptor antagonists in the treatment of opioid-induced constipation: a review" published in RESED Journal in September 2020, studies the recently launched Mu-opioid receptor antagonists for their safety and efficacy and concluded that PAMORA had shown efficacy in the treatment of OIC when compared to placebo and in different patient populations, as well as in the case of Naloxegol when compared to laxatives. Metilnaltrexona was studied and approved for patients with advanced cancer pain or other diseases, whereas Alvimopan and Naloxegol were for non-cancer patients. Thus increasing availability of Mu-opioid Receptor Antagonists anticipated the segment growth over the forecast period.
Furthermore, in February 2021, RedHill Biopharma Ltd. signed agreements with Cosmo Pharmaceuticals NV to manufacture two key products; Movantik(μ-opioid receptor antagonist), and RHB-204, currently in a Phase 3 United States study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease.
Additionally, the availability of Relistor in both tablet and subcutaneous injection forms, which is more effective at reversing OIC than other drugs, is expected to drive the segment and contribute to global market revenue over the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period.
North America is expected to dominate the overall opioid-induced constipation market throughout the forecast period. Dominance is due to the growing prevalence of various GI disorders among geriatric patients in the United States and a steep rise in the consumption of opioids in Canada in recent years.
According to the Center for Diseases Control and Prevention 2020, in the United States, the overall opioid dispensing rate in 2020 was 43.3 prescriptions per 100 people. Thus increasing number of OIC prescriptions in the United States boot the market over the forecast period.
Furthermore, according to the study titled "Naldemedine for the treatment of opioid-induced constipation in adults with chronic noncancer pain" published in the Future Medicine In June 2020, Naldemedine appears to be an effective and safe first-line therapy for the treatment of opioid-induced constipation in adults with chronic noncancer pain. Thus, rising product development in the country and several clinical studies are expected to boost the market in the region.
However, product approval and market launch by the key market players are anticipated to drive the market in the country. For instance, in December 2021, Sandoz launched an authorized generic of Narcan (naloxone hydrochloride) Nasal Spray 4 mg in the United States to help people who have overdosed on opioids. Furthermore, the increased availability of advanced healthcare infrastructure and earlier approval of OIC drugs owing to the accelerated drug approval initiative by the United States Food and Drug Administration is also likely to fuel the market growth in this region.
Competitive Landscape
The Opioid Induced Constipation market is moderately competitive and consists of several major players. Some of the companies are expanding their market position by adopting various strategies such as acquisitions and mergers, while others are developing new methods for the treatment and introducing new products to maintain their market share. A few of the major players currently dominating the industry in terms of revenue are AstraZeneca plc, Mallinckrodt Pharmaceuticals, Bausch Health (Salix Pharmaceuticals Inc), Merck & Co Inc, and Shionogi & Co Ltd.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca plc
- Mallinckrodt Pharmaceuticals
- Bausch Heath (Salix Pharmaceuticals )
- Merck & Co Inc
- Shionogi & Co Ltd
- GlaxoSmithKline (Theravance Biopharma Inc)
- Takeda Pharmaceutical
- Novartis AG (Sandoz)
- RedHill Biopharma
Methodology
LOADING...
